Florida Scientists Create First Drug to Target Lung Cancer

For over a decade, a team of scientists in Florida has been hunting for a way to stop lung cancer cells from hijacking the body's own protective systems. Now, they've finally found it.

Researchers at the University of Florida's Scripps Institute discovered the first compound that specifically targets GRP78, a protein that cancer cells use to survive and spread. The breakthrough could transform treatment for a disease that still has only a 25% five-year survival rate.

Inside our cells, heat shock proteins act like quality control managers, helping other proteins fold correctly and function properly. But cancer cells exploit this system, using these proteins as shields to survive stress and resist treatment.

Professor Eli Chapman and his team focused on GRP78, a protein found at four times higher levels in lung cancer patients than in healthy tissue. Higher levels mean worse outcomes, more aggressive mutations, and greater resistance to drugs.

The challenge was finding a way to target this protein without affecting the 12 other similar proteins in the same family. Graduate student Andrew Ambrose proposed targeting a small, claw-like pocket on GRP78 that had never been targeted before.

Chapman was skeptical at first. These proteins have remained unchanged across millions of years of evolution, making them difficult to target. But the approach worked brilliantly.

Using a rapid-screening technique, the team tested nearly 700 molecules. Their winning compound, called compound 12, proved 100 to 200 times more selective for GRP78 than other heat shock proteins.

In laboratory tests and in mice, compound 12 killed lung cancer cells directly. It showed particular effectiveness against cancers driven by KRAS mutations, the most common cancer-causing genetic mutation in humans.

The Ripple Effect

This discovery extends far beyond one compound. Chapman's team is now working to develop targeted molecules for every protein in the heat shock family, which could reveal exactly how each one contributes to cancer growth.

That knowledge could lead to personalized biomarkers, allowing doctors to match treatments to specific mutations in individual patients. It's a step toward truly customized cancer care.

The research team is already moving forward, refining compound 12's structure and testing it in more comprehensive animal studies. They're also working with the National Cancer Institute's specialty oncology collection to test the compound against diverse cancer cell populations.

Chapman holds about a dozen patents for related molecules, protecting this family of potential treatments as they move closer to human trials.

After years of focused work, these researchers have opened a door that many thought was locked.